Cogent Biosciences (COGT) said late Tuesday it has priced its public offering of 9.7 million shares at $31 per share and a concurrent $200 million offering of 1.625% convertible senior notes due 2031, for expected combined net proceeds of about $475.3 million.

The company said the equity portion was upsized from the previously announced $200 million.

Underwriters had been granted a 30-day option to purchase up to an additional 1.45 million shares and $30 million in convertible notes to cover over-allotments.

The equity offering is expected to close on Nov. 13, and the notes offering on Nov. 18, each subject to customary conditions, the company said.

It added that the convertible notes will mature on Nov. 15, 2031, with semi-annual interest payments beginning May 15, 2026.

Cogent said it plans to use proceeds to repay $50 million of existing term loan debt and fund development, regulatory, and commercialization activities for bezuclastinib and other pipeline candidates, along with general corporate purposes.